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INTRODUCTION 
Migraine is a common, paroxysmal primary headache 
disorder, which has high socio-economic and personal 
impacts on the quality of life. This pain syndrome is 
typically characterized by recurrent attacks of unilateral, 
throbbing headache of moderate or severe intensity. Most 
frequenty migraine-associated phenomena include nausea, 
vomiting, photophobia, phonophobia and allodynia.  
Epidemiological studies have revealed that the prevalence 
of migraine is 12% and it is most common in young adult 
woman. Two main subtypes of this neurological disease 
are the migraine with and without aura. Medications used 
to combat migraines fall into two broad categories: acute 
and preventive medications. Main reason for the limited 
therapeutic potential is the pathophysiology of migraine is 
stilll not fully known. However, the activation of 
trigeminovascular system (TS) is crucial in these 
processes. The TS consists of pseudounipolar neurons 
within the trigeminal ganglion (TRIG). The peripheral 
branches of these neurons innervate the cranial vessels and 
meningeal tissues, while their central afferents project to 
the nociceptive second-order neurons in the trigeminal 
nucleus caudalis (TNC) located in the brainstem and more 
caudally in the upper region of the spinal cord. 
TS activation produces a significant release of vasoactive 
molecules and various neuropeptides from the terminals of 
the trigeminal branches, such as calcitonin gene-related 
peptide (CGRP) and pituitary adenylate cyclase-activating 
polypeptide (PACAP). These peptides have important role 
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in several migraine-related processes, therefore the current 
migraine researches have focused on these peptides, as 
new potential therapeutic targets. 
Besides the TS activated neuropeptide release the 
importance of glutamatergic system is also pivotal in the 
mechanism of hyperexcitability manifested in migraine. 
Interesting and promising endogenous regulators of the 
glutamatergic neurotransmission include certain 
metabolites of the kynurenine pathway formed during the 
catabolism of tryptophan. Some of these metabolites are 
neuroactive for example kynurenic acid (KYNA), which 
is an endogenous NMDA receptor antagonist. Since the 
NMDA receptor mediated excitotoxicity play crucial role 
in the pathomechanism of migraine, the modulation of 
glutamatergic system may be another therapeutic strategy.  
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AIMS 
Our goals were to investigate: 
1.) the alterations of CGRP and PACAP in the 
experimental models of activated TS. 
2.) the potential link between PACAP and glutamate 
system. 
3.) the possible therapeutic effects of KYNA and its 
synthetic analogue (SZR72). 
Hypotheses of this study were that: 
1.) the CFA-induced sensitization may evoke elevated 
PACAP and CGRP expression level in the TS, which can 
be manifested in the alteration of mechanical hyperalgesia. 
2.) the KYNA and SZR72 may influence, presumably 
decrease the concentration of PACAP. 
3.) the different treatments may cause diverse effects due 
to the receptor specificity of drugs.  
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MATERIALS AND METHODS 
106 young adult male SPRD rats were used for the 
experiments and two different, TS activated animal 
models were applied. These methods are well-described, 
widely used and generally certified. 
1.) Orofacial hyperalgesia with Complete Freund’s 
Adjuvant (CFA)  
The right whisker pad of rats was injected with 50 µl CFA 
or saline. A mechanical allodynia test was performed with 
von Frey filaments before and after the treatment. Animals 
were transcardially perfused at 24, 48, 72 and 120 hours 
after the injection and it was followed by dissection of the 
TNC. The relative optical density of CGRP and 
preproPACAP was analyzed by western blot. 
2.) Electrical stimulation of TRIG  
Rats were pretreated with KYNA, SZR72, MK-801 or 
saline (vehicle). Next, the right TRIG was electrically 
stimulated, the animals were transcardially perfused 
following 180 min and the TNC was removed. In the TNC 
samples, the PACAP1-38 immunoreactivity was measured 
by radioimmunoassay, the relative optical density of 
preproPACAP was assessed by western blot analysis and 
the PACAP1-38 mRNA was detected by real-time 
polymerase chain reaction. 
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RESULTS 
1.) Results of orofacial hyperalgesia model  
A.) Orofacial CFA treatment resulted significant 
preproPACAP increase in the TNC 
Orofacial CFA injection caused significant (p<0.01, 
p<0.001) preproPACAP elevation 24 (0.58), 48 (0.69), 72 
(1.01) and 120 hours (0.85) after the treatment in the TNC. 
The highest preproPACAP concentration was measured 
72 hours after the CFA injection.   
Figure 1. Relative optical density of the preproPACAP 
protein in the TNC following orofacial CFA treatment. *** 
p < 0.001 vs. control group, ** p < 0.01 vs. control group, 
## p < 0.01 vs. 120 h group. Mean ± SD, n = 6. 
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B.) Orofacial CFA treatment significantly elevated the 
CGRP relative optical density in the TNC 
Significant (p<0.01, p<0.001) CGRP expression increase 
was observed 24 (0.99), 48 (1.26), 72 (2.36) and 120 hours 
(2.1) after  the CFA treatment in the TNC. The highest 
CGRP concentration was detected 72 hours after the CFA 
injection.  
 
 
Figure 2. Relative optical density of the CGRP protein in 
the TNC following orofacial CFA treatment. *** p < 0.001 
vs. control group, ** p < 0.01 vs. control group, # p < 0.05 
vs. 120 h group. Mean ± SD, n = 6. 
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C.) Orofacial CFA treatment decreased the 
mechanonociceptive threshold 
Significant (p<0.01, p<0.001) decrease was observed at 24 
(6.64), 48 (4.10), 72 (2.10) and 120 hours (2.77) after the 
CFA treatment in the mechanonociceptive threshold 
compared to the control measurement (7.77). The lowest 
mechanonociceptive threshold was detected 72 hours after 
the CFA injection. 
Figure 3. Changes in mechanical theshold before (0) and 
24, 48, 72, 120 hours after CFA treatment.  *** p < 0.001 
vs. control measurement (0 h) in CFA treatment group, ** p 
< 0.01 vs. control measurement (0 h) in CFA treatment 
group, ### p < 0.001 vs. contralateral side. Mean ± SD, n = 
6 - 24. 
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D.) Correlation between the expression of neuropeptides 
and the mechanical hyperalgesia 
Reverse relationship was observed between the 
concentrations of neuropeptides and the value of the 
evoked mechanical threshold (CFA treated whisker pad) 
depending on the time (pCGRP<0.001, RCGRP=-0.846; n= 
30, pPACAP<0.001, RPACAP=-0.792).   
Figure 4. Negative, linear correlation between the expression levels of 
neuropeptides and the mechanonociceptive threshold. 
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2.) Results of ES-TRIG model 
A.) Effects of SZR72 treatment on the ES-TRIG induced 
PACAP1-38 mRNS overexpression 
ES-TRIG resulted significant (p<0.05) PACAP1-38 
elevation in the TNC (27.49) compared to the control 
animals (19.31). SZR72 pretreatment prevented this ES-
TRIG-evoked elevation (14.68). 
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Figure 5. Immunreactivity of PACAP1-38 in the TNC 
following electrical stimulation of the TRIG. A: control 
group B: vehicle-treated ES-TRIG group C: SZR72-treated 
ES-TRIG group. *p < 0.05 vs. control group,##p < 0.005 vs. 
vehicle-treated ES-TRIG group. Mean ± SD, n = 6. 
11 
 
B.) Effects of KYNA, SZR72 and MK-801 treatment on 
the ES-TRIG induced preproPACAP protein 
overexpression 
ES-TRIG induced preproPACAP overexpression (1.78) 
was significantly (p<0.001) reduced by the KYNA (0.74), 
SZR72 (0.51) and MK-801 (1.04) treatments. Difference 
of the preproPACAP level between the MK-801-, and the 
SZR72-treated groups was significant (p<0.01). 
Figure 6. Relative optical density of the preproPACAP 
protein in the TNC following ES-TRIG. A: control group B: 
vehicle-treated ES-TRIG group C: KYNA-treated ES-TRIG 
group D: SZR72-treated ES-TRIG group  E: MK-801-
treated ES-TRIG group. ***p < 0.001 vs. control group. ###p 
< 0.001 vs. vehicle-treated ES-TRIG group. ++p < 0.01 vs. 
SZR72-treated ES-TRIG group. Mean ± SD, n = 6. 
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C.) Effects of KYNA, SZR72 and MK-801 treatment on 
the ES-TRIG induced PACAP1-38 mRNS overexpression 
ES-TRIG caused significant (p<0.05) PACAP1-38  mRNA 
release in the TNC (1.16) compared to the control group. 
It was significantly (p<0.01, p<0.001) reduced by the 
KYNA (0.80), SZR72 (0.66) and MK-801 (0.72) 
treatments. Comparison of the different treatments did not 
reveal any significant difference. 
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Figure 7. Relative mRNA expression of PACAP1-38 in the 
TNC ES-TRIG. A: control group B: vehicle-treated ES-
TRIG group C: KYNA-treated ES-TRIG group D: SZR72-
treated ES-TRIG group  E: MK-801-treated ES-TRIG 
group. *p < 0.05 vs. control group. ##p < 0.01 vs. vehicle-
treated ES-TRIG group. ###p < 0.001 vs. vehicle-treated ES-
TRIG. Mean ± SD, n = 5. 
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DISCUSSION 
Recent years the migraine research has focused on the 
neuropeptides as potential pathogenic factors and possible 
therapeutic alternatives. Nevertheless, alterations of the 
kynurenine metabolism have remarkable role in several 
neurological diseases. KYNA is a neuroprotective 
endogenous NMDA receptor antagonist, which may be a 
new agent in the therapy of migraine. 
Our results proved that the activation of TS cause 
significant and simultaneous preproPACAP and CGRP 
release in the central migraine-related area in the 
brainstem, thereby these data support the neuropeptides 
theory of migraine pathomechanism.  
Orofacial CFA treatment evoked significant CGRP and 
preproPACAP increase in the TNC. The neuropeptide 
levels reached theirs maximum at 72 hours after the CFA 
injection, correspondingly to the peak of facial allodynia. 
Another important result of present study is that the 
alterations of CGRP and preproPACAP expression show 
correlation with the change of mechanonociceptive 
threshold. 
ES-TRIG caused significantly elevated 
preproPACAP/PACAP1-38 expression both at the levels of 
proteom and transcriptome in the TNC. KYNA, SZR72 
and MK-801 inhibited the ES-TRIG induced PACAP 
overexpression. Remarkable finding of this investigation 
that the expression levels of preproPACAP were 
significantly different between MK-801-, and SZR72-
treated groups raises the possibility of the involvement of 
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additional targets of KYNA besides the NMDA (AMPA, 
kainate, aryl hydrocarbon, GPR35, opiod, etc.).  
15 
 
CONCLUSION 
Our results provided the first direct evidence that the 
expression levels of CGRP and PACAP simultaneously 
increase after CFA induced trigeminal activation in the 
central region of the TS. Correlations, which were found 
between the alterations of CGRP/preproPACAP 
expression and mechanonociceptive threshold have 
proved the influence of neuropeptides in the mechanism 
of hyperalgesia. 
Another important observation of the present study, that 
the NMDA receptor inhibition prevented the 
overexpression of PACAP in an experimental model of 
migraine. Remarkable difference was detected between 
the MK-801 and SZR72 treatments, which supports that 
targets at the non-NMDA glutamatergic systems may have 
therapeutic value in migraine. 
These data contribute to the better understanding of 
migraine pathogenesis and thereby to the development of 
more efficient therapeutic approaches. 
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